Bausch & Lomb holds up US launch of intraocular lens after reports Of calcification problems
This article was originally published in Clinica
Bausch & Lomb has delayed the US launch of its HydroView intraocular lens, after reports of a number of adverse incidents where the lens calcified and became opaque. In some cases, surgeons had to remove the lens due to the serious visual impairment it caused the patient.
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.